Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Xu ZhangNeurodegeneration New Medicines Center and Department of Molecular & Cellular Biology, The Scripps Research Institute, La Jolla, CA 92037.ORCID 0000-0001-6075-6000
Roman VlkolinskyDepartment of Translational Medicine, The Scripps Research Institute, La Jolla, CA 92037.ORCID 0000-0002-9786-0407
Chongyang WuNeurodegeneration New Medicines Center and Department of Molecular & Cellular Biology, The Scripps Research Institute, La Jolla, CA 92037.
Nima DolatabadiNeurodegeneration New Medicines Center and Department of Molecular & Cellular Biology, The Scripps Research Institute, La Jolla, CA 92037.
Henry ScottNeurodegeneration New Medicines Center and Department of Molecular & Cellular Biology, The Scripps Research Institute, La Jolla, CA 92037.
Olga PrikhodkoDepartment of Neurosciences, University of California San Diego, School of Medicine, La Jolla, CA 92093.
Andrew ZhangNeurodegeneration New Medicines Center and Department of Molecular & Cellular Biology, The Scripps Research Institute, La Jolla, CA 92037.ORCID 0009-0005-0130-5898
Mayra BlancoNeurodegeneration New Medicines Center and Department of Molecular & Cellular Biology, The Scripps Research Institute, La Jolla, CA 92037.
Nhi LangNeurodegeneration New Medicines Center and Department of Molecular & Cellular Biology, The Scripps Research Institute, La Jolla, CA 92037.ORCID 0000-0001-7187-1194
Juan Piña-CrespoNeurodegeneration New Medicines Center and Department of Molecular & Cellular Biology, The Scripps Research Institute, La Jolla, CA 92037.
Tomohiro NakamuraNeurodegeneration New Medicines Center and Department of Molecular & Cellular Biology, The Scripps Research Institute, La Jolla, CA 92037.ORCID 0000-0002-4246-7771
Marisa RobertoDepartment of Translational Medicine, The Scripps Research Institute, La Jolla, CA 92037.ORCID 0000-0003-0729-3961
Stuart A LiptonNeurodegeneration New Medicines Center and Department of Molecular & Cellular Biology, The Scripps Research Institute, La Jolla, CA 92037.ORCID 0000-0002-3490-1259
Funding
Viral Vector CoreP60AA006420 · NIAAA · SCRIPPS RESEARCH INSTITUTE, THE · PI AMANDA J ROBERTS · 2003 to 2026
$46.3M
Electrophysiology of alcohol in extended amygdelaU01AA013498 · NIAAA · SCRIPPS RESEARCH INSTITUTE, THE · PI MARISA ROBERTO · 2001 to 2026
$12.6M
Novel Proteomics Approach to HIV-Associated Neurocognitive Disorder & Drug AbuseDP1DA041722 · NIDA · SCRIPPS RESEARCH INSTITUTE, THE · PI LIPTON, STUART A · 2016 to 2020
$7.0M
Leadership in AD/ADRD Drug DiscoveryR35AG071734 · NIA · SCRIPPS RESEARCH INSTITUTE, THE · PI LIPTON, STUART A · 2021 to 2025
$5.4M
SYSTEMIC NEUROPHARMACOLOGYP50AA006420 · NIAAA · SCRIPPS RESEARCH INSTITUTE · PI HENRIKSEN, STEVEN J · 1985 to 2002
$5.1M
Omics Analyses of HIV and Substance Use DisorderR01DA048882 · NIDA · SCRIPPS RESEARCH INSTITUTE, THE · PI REPUNTE-CANONIGO, VEZ · 2019 to 2023
$4.3M
Dynamic Interactions of the S-Nitrosoproteome in Type 2 Diabetes/Metabolic Syndrome and Alzheimer’s DiseaseRF1AG057409 · NIA · SCRIPPS RESEARCH INSTITUTE, THE · PI LIPTON, STUART A · 2017 to 2020
$4.1M
Neuroplasticity of the Extended Amygdala CRF circuitry in alcohol dependenceR01AA021491 · NIAAA · SCRIPPS RESEARCH INSTITUTE, THE · PI ROBERTO, MARISA · 2013 to 2024
$3.9M
S-Nitrosylation-Induced Posttranslational Modification and Aberrant Cell Signaling in Sporadic Alzheimer's DiseaseR01AG056259 · NIA · SCRIPPS RESEARCH INSTITUTE, THE · PI LIPTON, STUART A · 2017 to 2021
$3.3M
Aberrant protein S-nitrosylation mediates Gene-Environment Interactions in AD/ADRDU01AG088679 · NIA · SCRIPPS RESEARCH INSTITUTE, THE · PI STUART A LIPTON, Tomohiro Nakamura · 2024 to 2026
$2.7M
Neuroprotective Mechanisms of S-Nitrosylated ApoE2 in Aging and Alzheimer's DiseaseR01AG061845 · NIA · SCRIPPS RESEARCH INSTITUTE, THE · PI NAKAMURA, TOMOHIRO · 2018 to 2022
$2.4M
Neuroimmune mechanisms in stress and alcohol comorbidityR01AA027700 · NIAAA · SCRIPPS RESEARCH INSTITUTE, THE · PI ROBERTO, MARISA · 2019 to 2023
$2.4M
California Institute for Regenerative Medicine (CIRM) EDUC4-12811HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS) NS122098HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS) NS123298HHS | NIH | National Institute on Aging (NIA) AG056259HHS | NIH | National Institute on Aging (NIA) AG057409HHS | NIH | National Institute on Aging (NIA) AG061845HHS | NIH | National Institute on Aging (NIA) AG065372HHS | NIH | National Institute on Aging (NIA) AG071734HHS | NIH | National Institute on Aging (NIA) AG078756HHS | NIH | National Institute on Alcohol Abuse and Alcoholism (NIAAA) AA006420HHS | NIH | National Institute on Alcohol Abuse and Alcoholism (NIAAA) AA013498HHS | NIH | National Institute on Alcohol Abuse and Alcoholism (NIAAA) AA021491HHS | NIH | National Institute on Alcohol Abuse and Alcoholism (NIAAA) AA027700HHS | NIH | National Institute on Drug Abuse (NIDA) DA041722HHS | NIH | National Institute on Drug Abuse (NIDA) DA048882NIAAA NIH HHS P50 AA006420NIAAA NIH HHS P60 AA006420NIAAA NIH HHS R01 AA021491NIAAA NIH HHS R01 AA027700NIAAA NIH HHS R01 AA029841NIAAA NIH HHS U01 AA013498NIA NIH HHS R01 AG056259NIA NIH HHS R01 AG061845NIA NIH HHS R01 AG078756NIA NIH HHS R35 AG071734NIA NIH HHS R56 AG065372NIA NIH HHS RF1 AG057409NIA NIH HHS U01 AG088679NIDA NIH HHS DP1 DA041722NIDA NIH HHS R01 DA048882NINDS NIH HHS R01 NS123298NINDS NIH HHS R61 NS122098NINDS NIH HHS RF1 NS123298
6 · The paper itself
Abstract
cAMP response element-binding protein (CREB)-regulated transcription coactivator 1 (CRTC1) plays an important role in synaptic plasticity, learning, and long-term memory formation through the regulation of neuronal activity-dependent gene expression, and CRTC1 dysregulation is implicated in Alzheimer's disease (AD). Here, we show that increased S-nitrosylation of CRTC1 (forming SNO-CRTC1), as seen in cell-based, animal-based, and human-induced pluripotent stem cell (hiPSC)-derived cerebrocortical neuron-based AD models, disrupts its binding with CREB and diminishes the activity-dependent gene expression mediated by the CRTC1/CREB pathway. We identified Cys216 of CRTC1 as the primary target of S-nitrosylation by nitric oxide (NO)-related species. Using CRISPR/Cas9 techniques, we mutated Cys216 to Ala in hiPSC-derived cerebrocortical neurons bearing one allele of the APP
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
S-Nitrosylation of CRTC1 in Alzheimer's disease impairs CREB-dependent gene expression induced by neuronal activity. · full record | Socratic